by ZACHARY BRENNAN CMS on Tuesday said it will only pay for Biogen’s Aduhelm and other FDA-approved anti-amyloid monoclonal antibodies for Alzheimer’s disease under CMS-approved randomized controlled trials. In a draft national coverage decision, which insurers nationwide are likely to follow, CMS said it’ll be looking for randomized controlled trials that “demonstrate a clinically meaningful benefit in cognition...